OptiScan (ASX:OIL) is a global leader in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, in vivo imaging at the cellular level in human and animal tissue and is used by leading research institutions and hospitals in North America, Europe, Asia and Australia.
Translational and Pre-Clinical Systems
OptiScan’s FIVE2 (ViewnVivo) system is the latest hand-held, confocal endomicroscope, especially designed for translational and pre-clinical research, enabling imaging in 3D at the cellular level. The system’s flexibility facilitates research in applications including live imaging of dynamic processes, assessment of dysplastic and diseased tissue, tumour margin mapping, imaging of molecular disease markers, blood flow and clots, barrier function, infection and pharmacokinetics across tissue types and organ systems. This research leads to enhanced knowledge as well as the potential for clinical and veterinary applications.
Collaborations with Multinational Medical Technology Companies and Clinical Applications
Our goal is to support medical practitioners and researchers with imaging tools that provide real-time information about the health of living tissue in a diverse range of diseases, with the aim of providing better health outcomes for patients and overall savings in time and money for the healthcare system.
OptiScan is developing the usage of its technology in various surgical areas both in its own right and in collaboration with leading medical technology companies. OptiScan’s patented technology has been integrated in a number of clinical systems marketed by leading medical technology companies including Carl Zeiss Meditec and Pentax Medical.
OptiScan and Carl Zeiss Meditec have entered into a collaboration project for the development and commercialisation of a miniaturised confocal endomicroscope for neurosurgery, known as the CONVIVO system. The device provides a real-time “virtual biopsy” during a clinical procedure, assisting pathology and the surgeon to determine cancerous and non-cancerous tissue and visualise tumour margins. FDA 510(k) clearance and CE Mark for the CONVIVO has been received and the regulatory pathway for other markets is progressing.
OptiScan has previously collaborated with Pentax Medical in relation to the development and distribution of the world’s first human confocal endomicroscopes for gastroenterology with over 100 systems sold.
OptiScan is currently working on trials and research in relation to breast cancer and is investigating additional clinical applications.